<SEC-DOCUMENT>0001144204-14-010929.txt : 20140221
<SEC-HEADER>0001144204-14-010929.hdr.sgml : 20140221
<ACCEPTANCE-DATETIME>20140221092135
ACCESSION NUMBER:		0001144204-14-010929
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20140221
DATE AS OF CHANGE:		20140221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dehaier Medical Systems Ltd
		CENTRAL INDEX KEY:			0001474627
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-178268
		FILM NUMBER:		14631845

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
		BUSINESS PHONE:		(8610) 5166-0080

	MAIL ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>v369379_424b5.htm
<DESCRIPTION>FORM 424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Prospectus Supplement</B></FONT></TD>
    <TD STYLE="width: 30%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Filed pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>(To Prospectus Dated December 20, 2011) &nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Registration No. 333-178268</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1474627|000114420411067953|logo.jpg" STYLE="height: 70px; width: 264px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>734,700 Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Warrants to
Purchase 220,410 Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>220,410 Common
Shares Issuable upon Exercise of the Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Pursuant
to this prospectus supplement and the accompanying prospectus, we are offering up to 734,700&nbsp;common shares directly to selected
investors. The purchasers in this offering will also receive warrants to initially purchase an aggregate of 220,410 common shares
with a per share exercise price of $11.86. The warrants are exercisable immediately as of the date of issuance at an exercise price
of $11.86 per share of our common shares and expire forty-two months from the date of issuance. A holder of the warrants also will
have the right to exercise its warrants on a cashless basis if the registration statement or prospectus contained therein is not
available for the issuance of the common shares issuable upon exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">For
a more detailed description of the common shares and warrants, see the section entitled &ldquo;Description of Our Securities We
Are Offering&rdquo; beginning on page S-6. There is no established public trading market for the warrants, and we do not expect
a market to develop. We do not intend to apply to list the warrants on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Our
common shares are currently traded on the NASDAQ Capital Market under the symbol &ldquo;DHRM.&rdquo; On February 20, 2014, the
closing sale price of our common shares was $11.95 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">As
of the date of this prospectus supplement, the aggregate market value of our outstanding common shares held by non-affiliates was
approximately $42,999,183 based on 4,776,000 outstanding common shares, of which 3,598,258 are held by non-affiliates, and a per
share price of $11.95, which was the last reported price on the NASDAQ Capital Market of our common shares on February 20, 2014.
We have not offered any securities pursuant to General Instruction I.B.6. of Form S-3 during the prior 12 calendar month period
that ends on and includes the date of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">We
have retained FT Global Capital, Inc. to act as the exclusive placement agent to use its best efforts to solicit offers from investors
to purchase the securities in this offering. The placement agent has no obligation to buy any securities from us or to arrange
for the purchase or sale of any specific number or dollar amount of securities. The placement agent is not purchasing or selling
any common shares or warrants in this offering. We will pay the placement agent a fee equal to the sum of 8% of the aggregate purchase
price paid by investors placed by the placement agent, including upon exercise of warrants issued in this offering. Additionally,
we will issue to the placement agent warrants to purchase 73,470 common shares on substantially the same terms as the warrants
sold in this offering, except that the placement agent warrants shall not be exercisable for a period of six months and shall expire
forty-two months after the warrants are first exercisable. The placement agent warrant and common shares underlying such warrant
are being registered herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">We
estimate the total expenses of this offering, excluding the placement agency fees, will be approximately $65,000.&nbsp;&nbsp;Because
there is no minimum offering amount, the actual offering amount, the placement agency fees and net proceeds to us, if any, in this
offering may be substantially less than the total offering amounts set forth above.&nbsp;&nbsp;We are not required to sell any
specific number or dollar amount of the securities offered in this offering. Assuming we complete the maximum offering, the net
proceeds to us from this offering will be approximately $6.1 million. We expect to deliver the shares and warrants to the purchasers
on or before February 26, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><B>Investing
in our securities involves a high degree of risk. You should purchase our securities only if you can afford a complete loss of
your investment. See &ldquo;<U>Risk Factors</U>&rdquo; beginning on page S-4 of this prospectus supplement. Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Per Common </b></font><br>
<font style="font-size: 10pt"><b>Share</b></font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td style="width: 72%"><font style="font-size: 10pt">Public Offering Price</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9.12</font></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">6,700,464.00</font></td>
    <td style="width: 1%">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Placement agency fees</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.7296</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">536,037.12</font></td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCFFCC">
    <td><font style="font-size: 10pt">Proceeds, before expenses, to us</font></td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">8.3904</font></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6,164,426.88</font></td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FT Global Capital, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>The date of
this prospectus supplement is February 21, 2014</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Prospectus Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%">&nbsp;</TD>
    <TD STYLE="width: 5%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">About This Prospectus Supplement</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Prospectus Supplement Summary</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">The Offering</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Dilution</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Description of Our Securities We Are Offering</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Legal Matters</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Experts</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Incorporation of Certain Information by Reference</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Disclosure Of Commission Position On Indemnification For Securities Law Violations</FONT></TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">S-10</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">General Description of Securities and Securities We May Offer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Special Note On Forward Looking Statements </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Legal Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Experts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font-size: 10pt">Where You can Find More Information </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Incorporation of Certain Documents by Reference </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><B>You
should rely only on the information contained in this prospectus supplement and the accompanying prospectus. We have not authorized
anyone else to provide you with additional or different information. We are offering to sell, and seeking offers to buy, common
shares and warrants only in jurisdictions where offers and sales are permitted. You should not assume that the information in this
prospectus supplement or the accompanying prospectus is accurate as of any date other than the date on the front of those documents
or that any document incorporated by reference is accurate as of any date other than its filing date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><B>No
action is being taken in any jurisdiction outside the United States to permit a public offering of the common shares or warrants
or possession or distribution of this prospectus supplement or the accompanying prospectus in that jurisdiction. Persons who come
into possession of this prospectus supplement or the accompanying prospectus in jurisdictions outside the United States are required
to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus supplement
and the accompanying prospectus applicable to that jurisdiction.</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>ABOUT THIS PROSPECTUS
SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">On
December 20, 2011, we filed with the SEC a registration statement on Form S-3 (File No.&nbsp;333-178268) utilizing a shelf registration
process relating to the securities described in this prospectus supplement, which registration statement was declared effective
on December 21, 2011. Under this shelf registration process, we may, from time to time, sell up to $25 million in the aggregate
of common shares, share purchase contracts, share purchase units, warrants, rights and units, of which approximately $18.3 million
will remain available for sale following the offering and as of the date of this prospectus supplement, excluding the shares issuable
upon exercise of the warrants issued in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">This
document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this common shares
and warrant offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated
by reference into the prospectus. The second part, the accompanying prospectus, gives more general information, some of which does
not apply to this offering. You should read this entire prospectus supplement as well as the accompanying prospectus and the documents
incorporated by reference that are described under &ldquo;Where You Can Find More Information&rdquo; in this prospectus supplement
and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">If
the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the
information contained in this prospectus supplement. However, if any statement in one of these documents is inconsistent with a
statement in another document having a later date &mdash; for example, a document incorporated by reference in this prospectus
supplement and the accompanying prospectus &mdash; the statement in the document having the later date modifies or supersedes the
earlier statement. Except as specifically stated, we are not incorporating by reference any information submitted on Form 6-K or
under Item&nbsp;2.02 or Item&nbsp;7.01 of any Current Report on Form 8-K into any filing under the Securities Act or the Exchange
Act or into this prospectus supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Any
statement contained in a document incorporated by reference, or deemed to be incorporated by reference, into this prospectus supplement
or the accompanying prospectus will be deemed to be modified or superseded for purposes of this prospectus supplement or the accompanying
prospectus to the extent that a statement contained herein, therein or in any other subsequently filed document which also is incorporated
by reference in this prospectus supplement or the accompanying prospectus modifies or supersedes that statement. Any such statement
so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement
or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference in this prospectus supplement and the accompanying prospectus were made solely for the
benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you unless you are a party to such agreement.
Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs unless you are a party
to such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Unless
we have indicated otherwise, or the context otherwise requires, references in this prospectus supplement and the accompanying prospectus
to &ldquo;DHRM,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; or similar terms refer
to refer to Dehaier Medical Systems Limited, a British Virgin Islands company with limited liability and its consolidated subsidiaries.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain statements
contained or incorporated by reference in this prospectus, including the documents referred to or incorporated by reference in
this prospectus or statements of our management referring to our summarizing the contents of this prospectus, include &ldquo;forward-looking
statements&rdquo;. We have based these forward-looking statements on our current expectations and projections about future events.
Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking
statements. Forward-looking statements are identified by words such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;project&rdquo; and other similar expressions. In addition,
any statements that refer to expectations or other characterizations of future events or circumstances are forward-looking statements.
Forward-looking statements included or incorporated by reference in this prospectus or our other filings with the Securities and
Exchange Commission, or the SEC include, but are not necessarily limited to, those relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%; font-size: 10pt"><FONT STYLE="font-size: 10pt">risks and uncertainties associated with the integration of the assets and operations we have acquired and may acquire in the future;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">our possible inability to raise or generate additional funds that will be necessary to continue and expand our operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">our potential lack of revenue growth;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">our potential inability to add new products and services that will be necessary to generate increased sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">our potential lack of cash flows;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">our potential loss of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">the availability of qualified personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">international, national regional and local economic political changes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">general economic and market conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">increases in operating expenses associated with the growth of our operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">the potential for increased competition; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-size: 10pt">other unanticipated factors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;The foregoing
does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk
factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements.
Please see &ldquo;Risk Factors&rdquo; in our reports filed with the SEC or in a prospectus supplement related to this prospectus
for additional risks which could adversely impact our business and financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;Moreover, new
risks regularly emerge and it is not possible for our management to predict or articulate all risks we face, nor can we assess
the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ
from those contained in any forward-looking statements. All forward-looking statements included in this prospectus are based on
information available to us on the date of this prospectus. Except to the extent required by applicable laws or rules, we undertake
no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events
or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements contained above and throughout (or incorporated by reference
in) this prospectus.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary
highlights selected information contained or incorporated by reference in this</I>&nbsp;<I>prospectus. This summary does not contain
all of the information you should</I>&nbsp;<I>consider before investing in the securities. Before making an investment</I>&nbsp;<I>decision,
you should read the entire prospectus and any supplement hereto carefully, including the risk</I>&nbsp;<I>factors section as well
as the financial statements and the notes to the financial</I>&nbsp;<I>statements incorporated herein by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>In this prospectus
and any amendment or supplement hereto, unless otherwise indicated, the terms &ldquo;Dehaier Medical Systems Limited&rdquo;, &ldquo;DHRM&rdquo;,
the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, and &ldquo;our&rdquo; refer and relate to Dehaier Medical Systems
Limited and its consolidated subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business consists
of the marketing and sale of home respiratory and oxygen homecare products and services as well as other medical devices in China.
We develop and assemble some of our branded products from components manufactured by third parties according to our specifications.
We do not manufacture these components ourselves. In addition to our branded products, we also sell a variety of products developed,
manufactured and assembled by third parties, which we refer to in this prospectus as our distributed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We sell the majority
of our branded and distributed products to distributors, and a very small amount to other end users. Distributors, however, sell
their products to the same end users, which include hospitals, clinics and individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have contractual
distribution relationships with over 2,000 independent distributors, keep close relationships with 3,000 hospitals and employ 70
direct sales and sales support personnel. We distribute our medical products through more than 20 offices in different regions
of China, and we leverage our customer experience centers to distribute homecare products to our customers. We have begun to develop
our business internationally by entering distribution relationships with third parties and employing our own direct sales force.
We have recently established an oxygen therapy center in Beijing to deliver oxygen and cross-sell homecare products through this
platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at Room 501, Jiuzhou Plaza, 83 Fuxing Road, Haidian District, Beijing 100856, People&rsquo;s Republic of China.
Our telephone number at this address is +86 (10) 5166-0080. Our common shares are traded on the NASDAQ Capital Market under the
symbol &ldquo;DHRM.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Internet website,
www.dehaier.com.cn, provides a variety of information about our Company. We do not incorporate by reference into this prospectus
the information on, or accessible through, our website, and you should not consider it as part of this prospectus. Our annual reports
on Form 10-K (and in the future, on Form 20-F), quarterly reports on Form 10-Q and current reports on Forms 6-K and 8-K filed with
the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) are available, as soon as practicable after filing,
at the investors&rsquo; page on our corporate website, or by a direct link to its filings on the SEC&rsquo;s free website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Shares offered by us pursuant to this prospectus supplement</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 64%; font-size: 10pt"><FONT STYLE="font-size: 10pt">734,700</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Shares to be outstanding after this offering (assumes
        all common shares offered in this offering are sold)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">5,510,700</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Warrants</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants to initially purchase 220,410 common shares will be
        offered to the investors in this offering and warrants to initially purchase 73,470 common shares will be issued to the placement
        agent as part of their fee. Each warrant may be exercised at any time on or after the date of issuance until the forty-second month
        after the issuance of the warrants, provided that the warrant issuable to the placement agent shall not be exercisable for a period
        of six months and shall expire forty-two months after the warrants are first exercisable. Warrants to be offered to investors and
        the placement agent in this offering shall have a per share exercise price of $11.86. This prospectus also relates to the offering
        of the common shares issuable upon exercise of the warrants. A holder of the warrants also will have the right to exercise its
        warrants on a cashless basis if the registration statement or prospectus contained therein is not available for the issuance of
        the common shares issuable upon exercise thereof.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to use the net proceeds from this offering for working
        capital and other general corporate purposes. See &ldquo;Use of Proceeds&rdquo; on page S-5 of this prospectus supplement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our securities involves a high degree of risk.
        For a discussion of factors you should consider carefully before deciding to invest in our common shares and warrants, see the
        information contained in or incorporated by reference under the heading &ldquo;Risk Factors&rdquo; beginning on page S-4 of this
        prospectus supplement, on page 3 of the accompanying prospectus, in our Annual Report on Form 10-K for the fiscal year ended December
        31, 2012 and in the other documents incorporated by reference into this prospectus supplement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Market for the common shares and warrants</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Our common shares are quoted and traded on the NASDAQ Capital Market under the symbol &ldquo;DHRM.&rdquo; However, there is no established public trading market for the warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants on any securities exchange.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;Unless
specifically stated otherwise, the information in this prospectus supplement excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">150,000 common shares issuable upon the exercise of outstanding warrants issued to Anderson &amp; Strudwick Incorporated, our placement agent in connection with our initial public offering exercisable for $10.00;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">7,500 common shares issuable upon the exercise of outstanding warrants issued to Hawk Associates Inc. exercisable for $9.60;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">100,000 common shares issuable upon the exercise of outstanding warrants issued to FirsTrust Group, Inc. exercisable for $4.00;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">450,000 common shares issuable upon the exercise of outstanding stock options under our 2009 Share Incentive Plan with a weighted-average exercise price of $1.45 per share;<B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">462,000 common shares issuable upon the exercise of stock options under our 2013 Share Incentive Plan;<B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">293,880 common shares issuable upon the exercise of warrants to be issued in this offering (including warrants issued to the placement agent), at a per share exercise price of $11.86 for warrants to be issued to the investors and the placement agent.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Before you make a decision to invest
in our securities, you should consider carefully the risks described below, together with other information in this prospectus
supplement, the accompanying prospectus and the information incorporated by reference herein and therein.&nbsp;&nbsp;If any of
the following events actually occur, our business, operating results, prospects or financial condition could be materially and
adversely affected.&nbsp;&nbsp;This could cause the trading price of our common stock to decline and you may lose all or part of
your investment.&nbsp;&nbsp;The risks described below are not the only ones that we face.&nbsp;&nbsp;Additional risks not presently
known to us or that we currently deem immaterial may also significantly impair our business operations and could result in a complete
loss of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Since we have some discretion in how we use the proceeds
from this offering, we may use the proceeds in ways with which you disagree.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not allocated specific amounts
of the net proceeds from this offering for any specific purpose.&nbsp;&nbsp;Accordingly, subject to any agreed upon contractual
restrictions under the terms of the securities purchase agreement, our management will have some flexibility in applying the net
proceeds of this offering.&nbsp;&nbsp;You will be relying on the judgment of our management with regard to the use of these net
proceeds, and subject to any agreed upon contractual restrictions under the terms of the purchase agreement, you will not have
the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.&nbsp;&nbsp;It
is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us.&nbsp;&nbsp;The
failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition,
operating results and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>There is no minimum offering amount required to consummate
this offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no minimum offering amount which
must be raised in order for us to consummate this offering.&nbsp;&nbsp;Accordingly, the amount of money raised may not be sufficient
for us to meet our business objectives.&nbsp;&nbsp;Moreover, if only a small amount of money is raised, all or substantially all
of the offering proceeds may be applied to cover the offering expenses and we will not otherwise benefit from the offering.&nbsp;&nbsp;In
addition, because there is no minimum offering amount required, investors will not be entitled to a return of their investment
if we are unable to raise sufficient proceeds to meet our business objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>You will experience immediate dilution in the book value
per share of the common stock you purchase.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the price per share of our common
stock being offered is substantially higher than the book value per share of our common stock, you will suffer substantial dilution
in the net tangible book value of the common stock you purchase in this offering.&nbsp;&nbsp;After giving effect to the sale by
us of 734,700 shares of common stock in this offering, and based on a public offering price of $9.12 per common share and a net
tangible book value per share of our common stock of $7.39 as of June 30, 2013, without giving effect to the potential exercise
of the warrants being offered by this prospectus supplement, if you purchase securities in this offering, you will suffer immediate
and substantial dilution of $1.73 per share in the net tangible book value of the common stock purchased.&nbsp;&nbsp;See &ldquo;Dilution&rdquo;
on page S-5 for a more detailed discussion of the dilution you will incur in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>There is no public market for the warrants to purchase common
stock in this offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for the warrants being offered in this offering, and we do not expect a market to develop.&nbsp;&nbsp;In addition, we do
not intend to apply to list the warrants on any securities exchange.&nbsp;&nbsp;Without an active market, the liquidity of the
warrants will be limited.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the
net proceeds from this offering for working capital and other general corporate purposes; provided, however, that none of such
proceeds will be used, directly or indirectly, (i) for the satisfaction of any of our debt (other than (I) payment of trade payables
in our ordinary course of business and consistent with prior practices and (II) the purchase of any of the securities sold in this
offering), (ii) for the redemption of any of our securities; or (iii) with respect to any litigation involving us (including, without
limitation, (x) any settlement thereof or (y) the payment of any costs or expenses related thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Purchasers
of our common shares offered by this prospectus supplement and the accompanying prospectus will experience an immediate
dilution in the net tangible book value of their common shares from the offering price of the common shares. The net tangible
book value of our common shares as of June 30, 2013 was approximately $33.5 million, or $7.25 per share. Net tangible book
value per share of our common shares is equal to our net tangible assets (tangible assets less total liabilities) divided by
the number of common shares issued and outstanding as of June 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Dilution
per share represents the difference between the public offering price per share of our common shares and the adjusted net tangible
book value per share of our common shares after giving effect to this offering. After reflecting the sale of 734,700&nbsp;common
shares offered by us at the public offering price of $9.12 per share, less placement agent fee and estimated offering expenses,
our adjusted net tangible book value per share of our common shares as of June 30, 2013 would have been $7.39 per share. The change
represents an immediate increase in net tangible book value per share of our common shares of $0.14 per share to existing stockholders
and an immediate dilution of $1.73 per share to new investors purchasing the common shares in this offering. The following table
illustrates this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="width: 91%; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt">Public offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 10pt">9.12</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt">Net tangible book value per share as of June 30, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.25</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt">Increase per share attributable to new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.14</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt">Adjusted net tangible book value per share as of June 30, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7.39</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt">Dilution per share to new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.73</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
specifically stated otherwise, the information in this prospectus supplement excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">150,000 common shares issuable upon the exercise of outstanding warrants issued to Anderson &amp; Strudwick Incorporated, our placement agent in connection with our initial public offering exercisable for $10.00;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">7,500 common shares issuable upon the exercise of outstanding warrants issued to Hawk Associates Inc. exercisable for $9.60;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">100,000 common shares issuable upon the exercise of outstanding warrants issued to FirsTrust Group, Inc. exercisable for $4.00;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">450,000 common shares issuable upon the exercise of outstanding stock options under our 2009 Share Incentive Plan with a weighted-average exercise price of $1.45 per share;<B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">462,000 common shares issuable upon the exercise of stock options under our 2013 Share Incentive Plan;<B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">293,880 common shares issuable upon the exercise of warrants to be issued in this offering (including warrants issued to the placement agent), at a per share exercise price of $11.86 for warrants to be issued to the investors and the placement agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
the extent that any of these outstanding options or warrants are exercised, there will be further dilution to new investors.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF OUR SECURITIES WE ARE
OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of
the Common Shares being offered hereby, please see &ldquo;Description of Share Capital&rdquo; in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The material terms
and provisions of the warrants being offered pursuant to this prospectus supplement and being issued to the investors and placement
agent (with some exceptions noted below) are summarized below. The form of warrant will be provided in this offering and will be
filed as an exhibit to a Current Report on Form 6-K with the SEC in connection with this offering.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants to be
issued to the investors will have an exercise price of $11.86 per share of our common shares. The warrants are exercisable on or
after the date of issuance and will terminate forty-two months from the date of issuance. The warrant issuable to the placement
agent shall generally be on the same terms and conditions as the warrants sold in this offering, except that the placement agent
warrants shall not be exercisable for a period of six months and shall expire forty-two months after the warrants are first exercisable.
The exercise price and number of common shares issuable upon exercise is subject to appropriate adjustment upon the occurrence
of certain events, including, but not limited to, stock dividends or splits, business combination, sale of assets, similar recapitalization
transactions, or other similar transactions. In addition, the exercise price of the warrants is subject to an adjustment in the
event that we issue or are deemed to issue common shares for less than the applicable exercise price of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established
public trading market for the warrants, and we do not expect a market to develop. We do not intend to apply to list the warrants
on any securities exchange. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the warrants
may exercise their warrants to purchase common shares on or before the termination date by delivering an exercise notice, appropriately
completed and duly signed. Following each exercise of the warrants, the holder is required to pay the exercise price for the number
of shares for which the warrant is being exercised in cash. A holder of the warrants also will have the right to exercise its warrants
on a cashless basis if the registration statement or prospectus contained therein is not available for the issuance of the common
shares issuable upon exercise thereof. Warrants may be exercised in whole or in part, and any portion of a warrant not exercised
prior to the termination date shall be and become void and of no value. The absence of an effective registration statement or applicable
exemption from registration does not alleviate our obligation to deliver common shares issuable upon exercise of a warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the holder&rsquo;s
exercise of a warrant, we will issue the common shares issuable upon exercise of the warrant within three trading days of our receipt
of notice of exercise, subject to receipt of payment of the aggregate exercise price therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common shares issuable
on exercise of the warrants are duly and validly authorized and will be, when issued, delivered and paid for in accordance with
the warrants, issued and fully paid and non-assessable. We will authorize and reserve at least that number of common shares equal
to 125% of the number of common shares issuable upon exercise of all outstanding warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at any time a warrant
is outstanding, we consummate any fundamental transaction, as described in the warrants and generally including any consolidation
or merger into another corporation, or the sale of all or substantially all of our assets, or other transaction in which our common
shares is converted into or exchanged for other securities or other consideration, the holder of any warrants will thereafter receive,
the securities or other consideration to which a holder of the number of common shares then deliverable upon the exercise or exchange
of such warrants would have been entitled upon such consolidation or merger or other transaction. Additionally, in the event of
a fundamental transaction, each warrant holder will have the right to require us, or our successor, to repurchase the warrants
for an amount equal to the Black-Scholes value of the remaining unexercised portion of the warrant on the terms set forth in the
warrant.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercisability
of the warrants may be limited in certain circumstances if, after giving effect to such exercise, the holder or any of its affiliates
would beneficially own (as determined pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder) more than 4.99% of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event the volume
weighted average price per share of our common shares exceeds 200% of the initial exercise price of the warrants for fifteen consecutive
trading days, we may be eligible to redeem all, but not less than all, of the warrants by delivering an irrevocable notice of our
intention to so redeem the warrants. Subject to certain circumstances in which we may be unable to redeem the warrants, a redemption
will require us to pay the difference between the initial issuance price and the highest volume weighted average price on any trading
day within a specified period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE HOLDER OF A WARRANT
WILL NOT POSSESS ANY RIGHTS AS A STOCKHOLDER UNDER THAT WARRANT UNTIL THE HOLDER EXERCISES THE WARRANT. THE WARRANTS MAY BE TRANSFERRED
INDEPENDENT OF THE COMMON SHARES WITH WHICH THEY WERE ISSUED, SUBJECT TO APPLICABLE LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in"><B>&nbsp;PLAN
OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Placement Agency Agreement and Securities Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FT Global Capital,
Inc., which we refer to as the placement agent, has agreed to act as the exclusive placement agent in connection with this offering
subject to the terms and conditions of a placement agency agreement dated as of January 28, 2014.&nbsp;&nbsp;The placement agent
is not purchasing or selling any securities offered by this prospectus supplement, nor is it required to arrange the purchase or
sale of any specific number or dollar amount of securities, but it has agreed to use its reasonable efforts to arrange for the
sale of all of the securities offered hereby.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will enter into
a securities purchase agreement with the purchasers pursuant to which we will sell to the purchasers 734,700 common shares of our
common stock and warrants to initially purchase up to 220,410 common shares, at a price of $11.86 per common share.&nbsp;&nbsp;
We negotiated the price for the securities offered in this offering with the purchasers.&nbsp;&nbsp;The factors considered in determining
the price included the recent market price of our common stock, the general condition of the securities market at the time of this
offering, the history of, and the prospects, for the industry in which we compete, our past and present operations, and our prospects
for future revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The placement agent
may be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any fees or commissions
received by it and any profit realized on the resale of securities sold by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act.&nbsp;&nbsp;As an underwriter, the placement agent is required to comply with
the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&nbsp;415(a)(4) under the Securities
Act and Rule&nbsp;10b-5 and Regulation M under the Exchange Act.&nbsp;&nbsp;These rules and regulations may limit the timing of
purchases and sales of common shares and warrants by the placement agent.&nbsp;&nbsp;Under these rules and regulations, the placement
agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: right; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; font-size: 10pt"><FONT STYLE="font-size: 10pt">may not engage in any stabilization activity in connection with our securities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: right; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time in
the common course of their respective businesses, the placement agent or its affiliates have in the past or may in the future engage
in investment banking and/or other services with us and our affiliates for which it has or may in the future receive customary
fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the securities
purchase agreement, we will be precluded from engaging in equity or equity-linked securities offerings for a period of 30 trading
days from closing of the offering, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we also
agreed with the purchasers that while the warrants are outstanding, we will not effect or enter into an agreement to effect a &ldquo;Variable
Rate Transaction,&rdquo; which means a transaction in which we:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: right; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">issue or sell any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of our common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market for our common stock, other than pursuant to a customary &ldquo;weighted average&rdquo; anti-dilution provision; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: right; font-size: 10pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">enter into any agreement (including, without limitation, an &ldquo;equity line of credit&rdquo;) whereby we may sell securities at a future determined price (other than standard and customary &ldquo;preemptive&rdquo; or &ldquo;participation&rdquo; rights).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed with the
purchasers that, subject to certain exceptions, if we issue securities within the 18 months following the closing of this offering,
the purchasers shall have the right to purchase 40% of the securities on the same terms, conditions and price provided for in the
proposed issuance of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also agreed to indemnify
the purchasers against certain losses resulting from our breach of any of our representations, warranties, or covenants under agreements
with the purchasers as well as under certain other circumstances described in the securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Placement Agent
Fees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have agreed to pay the placement agent upon the closing of this offering (1) a cash fee equal to 8% of the aggregate purchase price
of the securities offered under this prospectus supplement and accompanying prospectus; and (2) to the extent permitted pursuant
to FINRA Rule 5110(f)(K), a cash fee equal to 8% of the cash proceeds received from a cash exercise of the warrants offered under
this prospectus supplement and accompanying prospectus. In addition, we agreed to pay additional compensation in the form of warrants
to purchase 73,470 common shares. Under the placement agent agreement, the placement agent is also entitled to additional tail
compensation for any financings consummated within the twelve month period following the closing date of this offering to the extent
that such financing is provided to us by investors that the placement agent had introduced to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
warrant issuable to the placement agent shall generally be on the same terms and conditions as the warrants sold in this offering,
except that the placement agent warrants shall not be exercisable for a period of six months and shall expire forty-two months
after the warrants are first exercisable. Pursuant to FINRA Rule 5110(g), with limited exceptions, neither the placement agent
warrants nor any of the common shares issued upon exercise of the placement agent warrants shall be sold, transferred, assigned,
pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of
effectiveness or commencement of sales in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
there is no minimum offering amount in this offering, the actual total placement agent fees are not presently determinable.&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have agreed to indemnify the placement agent and certain other persons against certain liabilities, including liabilities under
the Securities Act of 1933, as amended. We also have agreed to contribute to payments the placement agent may be required to make
in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">After
deducting fees due to the placement agent and our estimated offering expenses, we expect the net proceeds from this offering to
be approximately $6.1 million assuming completion of the maximum offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Delivery of
Common Shares and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Delivery
of our common shares and warrants issued and sold in this offering will occur on or before February 26, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our common shares is Computershare Inc. located in 350 Indiana Street, Suite 750, Golden CO, 80401 U.S. Our transfer
agent&rsquo;s phone number is 001-303-262-0678 and facsimile number is 001-312-601-2312.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common shares are
quoted on the NASDAQ Capital Market under the trading symbol &ldquo;DHRM&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the
securities being offered herein is being passed upon for us by Kaufman &amp; Canoles, P.C., British Virginia Islands counsel. Certain
legal matters will be passed upon for the placement agent by Schiff Hardin LLP, Washington, DC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of our Company appearing in our annual report on Form 10-K for the fiscal years ended December 31, 2012 and 2011 have
been audited by Friedman LLP, independent registered public accounting firm, as set forth in the reports thereon included therein
and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon
such reports given on the authority of such firms as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents filed
by the registrant after the date of filing the initial registration statement on Form S-3 of which this prospectus forms a part
and prior to the effectiveness of such registration statement pursuant to Section&nbsp;13(a), 13(c), 14 and 15(d) of the Securities
Exchange Act of 1934 shall be deemed to be incorporated by reference into this prospectus and to be part hereof from the date of
filing of such documents. In addition, the documents we are incorporating by reference as of the date hereof are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 98%"><FONT STYLE="font-size: 10pt">our Current Report on Form 6-K filed on August 26, 2013, as amended on February 21, 2014; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K filed on April 4, 2013 and April 26, 2013;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">our Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 18, 2013; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; background-color: white">the description of our common shares contained in our registration statement on Form 8-A filed on March 16, 2010 and as it may be further amended from time to time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained
in a document we incorporate by reference will be modified or superseded for all purposes to the extent that a statement contained
in this prospectus (or in any other document that is subsequently filed with the Securities and Exchange Commission and incorporated
by reference herein prior to the termination of this offering) modifies or is contrary to that previous statement. Any statement
so modified or superseded will not be deemed a part of this prospectus except as so modified or superseded.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may obtain a copy of these filings,
without charge, by writing or calling us at:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dehaier Medical Solutions Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Room 501, Jiuzhou Plaza, 83 Fuxing Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Haidian District, Beijing 100856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+86 (10) 5166-0080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Investor Relations</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only
on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized
anyone else to provide you with different information. You should not assume that the information in this prospectus or any prospectus
supplement is accurate as of any date other than the date on the front page of those documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a registration
statement with the Securities and Exchange Commission under the Securities Act of 1933, as amended, with respect to the common
shares and warrants offered by this prospectus. This prospectus is part of that registration statement and does not contain all
the information included in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For further information
with respect to our common shares, warrants and us, you should refer to the registration statement, its exhibits and the material
incorporated by reference therein. Portions of the exhibits have been omitted as permitted by the rules and regulations of the
Securities and Exchange Commission. Statements made in this prospectus as to the contents of any contract, agreement or other document
referred to are not necessarily complete. In each instance, we refer you to the copy of the contracts or other documents filed
as an exhibit to the registration statement, and these statements are hereby qualified in their entirety by reference to the contract
or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration statement
may be inspected and copied at the public reference facilities maintained by the Securities and Exchange Commission at Room 1024,
Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549 and the Regional Offices at the Commission located in the Citicorp
Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661, and at 233 Broadway, New York, New York 10279. Copies of
those filings can be obtained from the Commission&rsquo;s Public Reference Section, Judiciary Plaza, 100 F Fifth Street, N.E.,
Washington, D.C. 20549 at prescribed rates and may also be obtained from the web site that the Securities and Exchange Commission
maintains at http://www.sec.gov. You may also call the Commission at 1-800-SEC-0330 for more information. We file annual, quarterly
and current reports and other information with the Securities and Exchange Commission. You may read and copy any reports, statements
or other information on file at the Commission&rsquo;s public reference room in Washington, D.C. You can request copies of those
documents upon payment of a duplicating fee, by writing to the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DISCLOSURE OF COMMISSION POSITION ON<BR>
INDEMNIFICATION FOR SECURITIES LAW VIOLATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">British Virgin Islands
law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of officers and
directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to public policy,
such as to provide indemnification against civil fraud or the consequences of committing a crime. Under our memorandum and articles
of association, we may indemnify our directors, officers and liquidators against all expenses, including legal fees, and against
all judgments, fines and amounts paid in settlement and reasonably incurred in connection with civil, criminal, administrative
or investigative proceedings to which they are party or are threatened to be made a party by reason of their acting as our director,
officer or liquidator. To be entitled to indemnification, these persons must have acted honestly and in good faith with a view
to our best interest and, in the case of criminal proceedings, they must have had no reasonable cause to believe their conduct
was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling
us pursuant to the foregoing provisions, we have been informed that in the opinion of the Commission such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable.</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>734,700 Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Warrants to
Purchase 220,410 Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>220,410 Common
Shares Issuable upon Exercise of the Warrants</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FT Global Capital, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February 21, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1@$(`P$1``(1`0,1`?_$`*L```$$`@,!`0``````
M``````D``P@*!@<"!`4!"P$!``$%`0$```````````````$"`P0%!@<($```
M!0,#`P,!!@0%`P4````!`@,$!1$&!P`2""$3"3$B%$%183(C%0IQ@4(64F(S
M)!?PD:'!0S<8.1$``@$"`P8"!P8%!0````````$"$0,A!`4Q05%A$A,B!G&!
MD:'!,D*QT6(4%0?PX:(C)/&RPD,6_]H`#`,!``(1`Q$`/P"_QHL`,*%J/3[/
M_74=^$'26TJZJ#8%H`_?3_Q_+6-F91S<%:AQKP(E-+%FI;YRA'6NBNW:%(O-
M``AVQ-["E(`B<1IZ]/36WTW3+ER*C]'I5:F,[L/6:;QEF1A<T[*6]-N6RA[V
M6"ZL;=Y8K<+KL_<8/[:2.<=OS;:^4D!P+4X]WJ`:RL[I]VS%.5.G?BMI*N1K
MO)B$$!`!`=P"`4,']0"'XOYZYR-;>9:W&0G6*:.(I^[^/_7V:V'5@7%/PC@=
M*!K%G>2FH[ZE#QQ.>KQ2+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0"T`
MM`+0"T`M`+0"T`M`-`<U:&3$H5]=P"%/M&GIJ*IX(#2IQ)6I1,;U+3VEV_88
MYO:`UUCSRLKBZE]J*J5-498N9]`65,2K(#$4C"IOWZ;0!D9`T0W$QI`[)FT'
MOF<%3IM&A@#Z@.MMY;TZ,]25NXZ.:HL5MW+UF)G6X6:\P8=[7@Z%G)R,I/\`
M8)#M@F9Z6V&."-L.-_:NN.:`(K2<4T.B8CE!(14#>7WEKU]JTW0H148[;LEX
M5U156MU:;<35*\WCN(HW!E]RZ<%49OT+.%M-=R%O-J<`;86O1^51Q:<VFFX,
MJ3_B#+J31UV2KB=1L9DF`NS"?KD9CRWF4O[JK&,FJN4/%'B\/F7LQV$]];OB
M%NX>\K%>0-@(M[IM]"RLS6$X3M3-6,=ZGZC9MT(%506>MD%U#.5K<<NV*X-U
M!`_<)M$%!`.OCFMZ0\KGYQBT[<_%%N4<5OQW[<#<Y=N=E2?`F:1PX,8`%,!(
M4!(H)0&IE*@)%4^HAV3D`1IU$*AUUS-]2CLV%T[0U"@B8I>H?B'U^X.H==8\
M+-US4W2B94VJ#VMD4''<%1*`AN#Z?9TJ%?Y:`87641%+:D4Y#F$AU!5(F"9A
M``1#:;JIW5!`O0>F@.LL_P#CG[*@I'7^.HOL`P(D_+W&,(JJ&$I";0]1]/70
M#J+P%4>Z($`U/])!0CLP#UZ@*(B!P_@&@/J;K<GW%"'3]0*0Z1R**T]!(F;W
M]?LZB&@.(.E1(10[?L$-NWG74*3M4IMW$-M$VZH^GV:`^%=&(GW%%$%RB>@&
M;U*!2T&FZIU-PB-`Z4]=`?%'QTD2**ME2**&VBDF47)D0$IA*JJ5(-P$`0"O
MI2N@'"N0)V"+&W'6*7:HDBH"`F$H"-#B)P*!O4`$?30#2[X4%@2,FD4!_"95
MTBB)_O(500$P?P^N@'SN*%W$$IZ$,.TH"<!/M$2)]TIM@&,;IU]?IH!H'2E"
M*=LYB*EVD3!LL"A%@$:]X1$033^\0#[:Z`[X5H%?7Z_QT!UU5%"B`$`A2%VG
M555J!`)7W`40$ONH'\M`(S@`$@E+W$SEJ4Z8@;H'XAH%:E"H:`7>J;8'M,;J
MF)B&VF#Z]:@`C_/0"*L<RQB;![8%J14`$2F'Z@(AT"@:`:37.)1JJ@H('.&Y
M%-02``&$`+7N&]Y0Z#UT`CNC%,F4!2,94^PI3CV1,(%,<0)O-[S`!?0.M.N@
M$1T"H+=LZ8F2-VC%(/>,10U`+O[9O0!,`B'J`5T!R,NJ4##V=XIB4IQ(8/=[
M0$QB`-1``$?3J.@.8N`-T1V+*>W<F"A"F*`TK6M>H:`8.]"JH)E/5`"BJ4[=
M;H!A'J4P;0-0`^F@.:+D%R=Q!1!P3H%$C4,4?ZMXB<P`(?92N@-)7/GRR[8<
M/(]PRN:4DFA3F,UB8"3D`,(5H!%6J"A!]/36QR6@:I.2:C'Q?B1B//99;W7T
M,AAFGG?>]GQYU;,PK(&$Z7=2GKYDRV?%(^\Y>VHWF46BB@$`H&$X*``[J!U#
M7=:7Y(O9J5+[:MT7RRC6N_<^1/ZGEH[W7T,&C?GD2Y8W"\[4?>^*[(C]JAWB
MUN6W(7LNT:%_UTE'#"><M7B1R=#D*0#&`/:(:ZZU^V^0@HJ4[Z<I*GBA6JV?
M3@8.HZM:E;2M;:\&0NM7E!<H7<\Q?<MZ$5N&2D%[EP?D2<B'$?"60X6$$Y6S
MKICG1TR3]OS(`@)""=/LF1'W>[7K^6\JYCL.=Y4R\[=&U*-538UA@]M6:!9R
M*Q7'F=2ZKJ.QDFSM!FXE(Y_!2Z3N!64,0+FA2+1XW;QUD&]"JMKRAGHLW<,L
M.U=%!DZ*!#@<1+<OV,OF[BL6Z]<7ALQ]+H4_FX_PF>_A+E#(<?LJ6CG.'FI:
MZFT`QB;(R_-'344-?7'VY'#(,?7[+-TR4<RMG_`:-9-T0"BFXDP!7:)P`>"\
MV^2,QG+4NJ*73XE24%BDZ+9L-SE=?TZQ;5J[*7<6WPMEE"\N2D(M\-OC%^C+
MLQ;1$PO*Q[@C^.4BWC9).&8QCA$3IOWTBW=IK"BF8RJ>TP"%0'7@-S1,ZTW>
M2[D9SC*DE\T71^\V,-5R5Y^"3>"^EHVU96;862$D9-.B#+E4:H"@3W*G?+$(
MHK'()A47$DP0WJND"AW&R:*IC@`)GIB9G3;V7M*;2Q=-JX-_8C,MWK<UX62"
M*X24`IDA%5,Y0.15(HJ)'*8*@)5"5*8!`?MUJ2LX%70`QU!/M#=LWJ!L((E(
M`CL.:@&`*4$0'UZ:`K=?N"/*QE+@-BJRK4X],3N,RWS=46Y-<$M;\JM9EI6U
M'R#%<DK(W,FJVA6BCM1)=+M*J@([`Z=="J,)2V$/N&ODC\AUW<$+>Y.W7R`X
MX7Q>%XY/DH-&'OMY&6#"1\`U0@2JJMY*6N=DA)I-!=*B)$3@)Z4#UU%2OM3(
M*^0G]PMY"L+2MOV%9<]QX0GY1O\`(_5<33\=>:"R8'`@G2687+,H&.0?4@=?
MMU-1VIF]N%7F3\F$YAV*R!>61.'>0T,BN!)!*7U=\=:=UVJY*D0QFMR1BM^1
M@L3)@N7\T[=%(P@(`7VCH6GA@6%_&ORVY%<I[5R/,9G0P2#>T#M&<)=F)[J:
MW0P,Z70>'D4YMNRN6:!$J1FZ9T#;DP.4#TK3H!75Y)^=KGMQ?\CA,!P"F.N2
M&+5[EJ-NV*R4=706V!>@T7`L7'RS]\E(-47)%.T*8J#VS!3H.A,8N3HB='EK
M\I?.*QX;"EL>/7&#]>Z+JM:W[[O^\+JC%VBT4TG6,4JVAG5KR*;=^T$SF6`J
MISB&T2UZ`&A<[,SN\<^5?G.AL81TIDRV.&%Z3%P')/"$QD>*AY"!9R;L#"TD
MQ-D%%-LY9JN@34(8A-I@'H4`II4=F9D-M^47R*WQDXF-82W>$ZL]`W;&0%T1
M3?+,$5R9%RJW2<!"N%K_`%4Y58IEMH%1*81$-"W*+BZ/:'CS/GZU^-W'*Z<\
MY^E(*U&5D68:Y;H#YJ:<1^NLF!7;2+AU#+B>26>R94VZ!$U#F64.!2U$::$%
M#/$7G?\`+_S5Y3S-B\2GEMW9;<K=[R4B[3AX;NA;V.&+SLB]E9<SI9"-DC-F
MBAP:+`58]0H'N#0%DM'R.>4^.9$;R7CRC!>Q<>S"2,]R7$L7RJI4_CB[7CUA
M*NU4DET#*)IF`!$#A3Z:%SM3W$7^6'G[Y7\&XNSISE/PFB\:Q-Z2SN)BB2%]
MLE'+DS9)HJ+@Z8'(9NR5!V`$6,';,8I@`1VCI4=J>W"A,GP[^7C)GE8/?EW$
MX\N,8XELE5S&I7P>2.NUDI$1'X[*.*J7;("X*@83'2$2I[0J'N#0I<7%59#G
MS4^>7./C3Y-V;A2Q,00-WP\K;![H=OWLL1%51@*C1)(>T"Z9Q4,9R'Y84/\`
MST*3#Q\Q/D>CN/N-N2F0K+XE81QME.,1F;*"\[M_3YF5CUD$G)#K0,E?K638
MG%)<M2J%`0$=`;;Q1Y./)1G.T6U]XO4X%SMLNESM$G?_`"A$L5S+-SF1<K*,
ME\E"LDBDL004./M*80`?70&:N^<OE@7<!$Q*7C^F;E.NW3C("'S=:CF3D5E'
M22*J39`N27"JE6YSB`E+41"F@#LVQD*\K9P"EDW/,/&VY=-M64_NO)$1:QC.
MXQ@$3$N)&4!@N"SXSU$B"`FWD4,'_;0`<<B>>K!\GPIS9R\XQVPZR@&#[G6M
M:XK?E3N(1,J[=VW;*F,LY(EW"`1>H"%.H>N@(,\6_P!P5SDYN6K*WIQ@\<[S
M)$/#(_ITK*Q=V`@E$S2R!#$2.55-8')"F<$ZE$`H-/IH#S[!YR?N.(C++VX;
M^X#DF,8**JJ-;3!W\59DV*(F(FI)$,!7ZSHH[$R)@!P,7ZU#0$M6/DZ\NWSV
MZ:OB6N)%%R_03>*-[H-_M6G<(58[E,6QS(.NV(F*D:AS?2N@"X\BECL91LBH
MS1<C(D[)"ME21AQ`1$M!66,%1Z^NNZT.ZNB*5>GFZO:::_8<6VP4.<XX[45B
M?V@JJY*G^4\55F[L>IIB8QBD32AGIX]-`#"(@4Z(J`(B(C00`/8]"CUT:V&G
MOR2J#=R"UE$2KKO+HCX-H6H&;.Y>W8Y]01$0(%JG31N$Y!I0RE!(E_7ZAKT?
M(:>\S.,7N:X'-ZIG^S;4EL;YD-LGPZ=V6XI&RSTR:Y5!/`7"Q.":Q54R[D^V
MJ2H_C`HZ]/O9)6M+Z76E.1H_U=KA[&/VEFHN0K*6&X%UXR[5$XBQ\E$0J#NT
M<Q6BFZ0M++L:02G$JUS,7$HG*$H=/<=*I4Z!7A='T_O:@TJM]7(?J[Y>QF%M
MLA71<U[0>,;)CVBV2)6XY1HVMQ&JEOA`S0+K9`B)K\P0)9%NRJ+-9!452`11
M!$.Z-:&WOF#3:.<'7#T&9EKCO4N<0W?'>Y[3P_9=G6-`7"[=P$!\^%CYV97%
M7YMSP_?A[WR*590I`5LEQ."LT@U.J)Q?-0*HJ)B[O`-5T&^W*Y?BHR=R5$G&
MCC5]+?-K%\SJ=.2W<$3QL*['1CL7#1U&L#1S=Z^7DI58$WL'#.2JB9X_(=9+
M;>-U]\K<J9B@8$'J@E2"@&+PNLZ?V<A=?"-=QU>7VH)+A%_=\M:J<C<)?T8C
MA0?[3C'!P*LO$]ONMU%2*&[AQ40KZ4Z=?37D2V&Q-Z`D38)5B]U!8QCF`1#M
M-MJ550$W2A#*E,-1'U'0%-7]W%8N09#!>(KT"X+?BL;-;@)#2+1`J2;V=<*/
MFWQXYRNHL=442'=%$IB[0$QA"NCV&18W@'>1\[>')KPO<3X3#F$9=F]PSE"5
MMZ9+CU"8?JOG3Y2W3MI"7912KET[3'O@)BEVF$H4#5)?9GEP6SQ\"/\`%BM!
M\8LCA<&'7SY3EL]<8IR4]/,,'4E`*E*N95BI4/C-7`!Z^NI!G+BV^(8W=Y4'
M#+B_DT+6RC`-EN'[8EDY(9?!D&@W&9RLS:%02^,L<7K7<`%)Z!TU)@R^9AQ?
MVFN&<K8EXAYMF<JX]NRQ#7;=\`_MMI=T1<4.E+116<P#DP&N3JX^**Z91%,0
M`O<]WJ&A!7U\KV2F5H>=!,_'^V6N*[\Q_EFQ8-]<J20O8I\>7?+IR#AVBL99
MN9)5LV5,8`VAU^[0N6OG/3_<:9B=3/D$B&EA9FF)>,88EL>U+C/B^>91T'&S
M;6*M[Y`2P)$=(M!^6Q/N`QB4$/IJ#*2H=8O&BS9"<XY0F,Y*X;ILS(V.+(E<
MX94N[/C"'8VK<4L2$?W2+%NK,Q:*B3:745*0H%4J`?70D'`O`V)ASR?65:EF
M7S./\;6!R+M,CS(RMV'_`$=XQ7>L%56B4C\@C.6;?.<4[I3*!7I74F+>^8_5
M0R-@O#W+C!]NV)D>-BK_`,?RD9;4HF@21!=A(BSCHZ1BEG0MG-'!0>(IF$M>
MM*_70M%-CGGY+,!>(GE4K@[QG\=K")>*;+MY;NI-LLJF_N,P*G+;C50'J9D3
M'2!`HE*:NXXZ!8N@`CFMR1YN95YA.[HR=?\`>^'\PY++8UP/,61$M.,X5H\*
M<'%N,@:"[5[:4HW%$1`#@`@?[]09ZV!,+G\M;S*W)W!>'?*!Q;LV\+&LA:%L
MJ\4GDB\0;QD`]%HC$W6\.ZFEC(NW0_(WB(@402"@!0=0.2+]W$_!7'?`^&H"
MW>,EIP=IXNE8XUPPC>W52+,':,L1%8IS+%57,X[0%H4XF'Z]=5;C%N-MX[BA
M+^[;_P#T&QV'3_X4)ZUI3YD/U&@@-`#[-"T$'L3"GB[OSA/P)D?(*ZR"M-HX
M\C7>/86W86\9"WYI-.,BC@"J;1J_*L42B%:'#IH`%?F[NCB7(<@,4->!4),X
MXQ[!XX:V9<T=:X7M!R4U<SY:!5:]^V5GQ7:3L6[%Q50$"@M43!T'0%E_A1R=
M\1>(.._&,F5<;7#$9QLZS;*93$Y,8_RS/32-YIQS!B^FI,L<8.V@H^.>BRQ.
MQN,!1J80T!99RBL7-O%O)ZF/A<S)L@X?O!&T!;,7<2I(#,6C((0K?XDH0RM'
MBRR9#)T`X@80"@Z`_.CL:WKYXU^*KR"<9LU8>REB7)=ZYJDYN#N=[:TNE;LR
MU3F(YP*2:KF+41%$Z;<2B!5/30!,?VWN`YWE1X[N5.&X/*]XX3E;BO&,2)?^
M/U&;:98.&D3;3<3E;NV$@9N83,JB42`([J_70&V_(EQ9>^,#";G+69?+!R3N
M"=3@9B-Q[C=P_@`?WE<3)H"S1T5%M:(N%DH!=TDLKL$M"G]W00T!T?VYL1Y7
MN1&6V_*W.6=+^><5&\4YCFML7B#/=D>04%9:,GFQ!8MG)T&:"A`/V@"M0ZUT
M!;RR];,Q=3,QH6++(NT0-LW3$(WH("/X`<E[A1#^.M_I&<MV+BC<>&[:R+]O
MJASH!!YM7Q=6#7-B0LMCF-F;MOZ170C&EPW]#,()O;4(HW7N20=-XR0B90YB
M,WH>\%P+0O3J`Z]_\H7K.>MOL2K%.C>RC]9P^JMVGXMX"?(>2.1=Y/XMM'O+
M2L7^XDD?UZ)M6TGTNV9Q4B\=M[952N>X5KB;E<=YJZ$Q"K;EPI0!H&O<-,MJ
MQTRERX'!ZE-YB*BCQN.F)LD\C.4&*\;9)Y#*IXXNV5N,))I(Q5OV^5*+A3P9
M68M')(E@.YU^HJE*("-1+]VLCS?YCMZ1H-[/2BY]JVY=*JJTW)[$:JUDIW;L
M;=:=3I6N!.CRM>.7'O!C'41FWC1,**2M[332SKLQG+RI9"4R(E.(JNW4S%$5
M4*Y!9BM'%JJCU("X!4*]?,OVI\]_^@UIY+-6E#,).:<?EZ4TDL6WU8X[C(S.
MESRZ33;BR%G'.RF&+XJ:N:YK@,QOZ\H2.;Y!O=JDF\<8XM2541D;2Q/8Q%$G
M(2>0+H!N!)`Y0=J-FC-R98A#4.3U[S!GH?J=ZSN3X,V^G1Z+48O<35MN]Y9]
M(?J\I&-E(YN[B+6A,8PQ2."N9J(,C&V[C2T7"0KN96U;-4;EF+BDP4<$,^A`
M`RZ1%!3-YIK-N$;#Z77%O'G\#K].==H57ACCJ:S'E=5C+NCFLS$$Z6Y\OS,8
MFI(6QFO+,@U5&)&`DT1<(%A[*&4,BL@V5%`%F=#!TIKY_P#-^H1LVIVX4=VY
MX."2VM^ZBIQ.LRRK3@'S!-,H)@5-,H(@!4@*0H`D4`V@5*@?EE`O2@4Z:\C-
M@.CZ)A]!,8!#Z"`UJ`A]:UT!5)_=NG11X(8X!91D@W/E=-N(N2^BR_\`;Q&O
M8#<4`.5P8!]!U#,BQO*Q'&KFUQVP/XUK3PK?%\Y';9?)EYY<QD[+_2RJ)PS=
M.WE^Z47,!)(=Q--L?:94#%"G4!T+Y(.!7O;EAP(SOR0X99KSS"YOP3+H%R=A
MB<3LF6GKKMY9BN\9R<0P+8Z+XR9DVRQ1[("`C]-`:+M#FMAZR<08N;9\O3EY
M<W+"XY0T1D''L/#6K&'M*/9D9D:M8:*+C(SHR0N'BU3&,J<VP*F&FI,&6UE\
MSQ%8.G\1<3X"3NBY\HSCO*.R_(Z#RLZAE9>V(>6:I+-(Q*.BX2#&/.!3AWDU
MDMP"4M`+UJ(*`7E4*`>=FY`0`CD7F;;(2>H++&21535GE$E`74`Z>RB2I@`P
MB%*^NA<M?.;2_<N63CW$'D=MAA8+2$LF&EL=V=*W0DLX`Z<R[5A81<PE%5P.
M]4RBHB(U$1$1U!E*N\R9EC#A$^S+PVY&8]Y$0<1C6V[)QJ3/V%;G0O!U`3MT
M-X2(0NQLFFQDV)P(XGRJG_*4`FZFVA>FA(.2[2X9R5Y4&7]D0\>RP-?/)MNX
MM:$CEWQ&DA$HOOB+1,.@_=.9(B;B01,8O<.HH4P]!"@4DQ;WSGZ$OD=\C6`/
M%UPF;0T1/15EY:E\:1L5A;'+MVHZF5968:DC&S]4KA=5XHG%"N9R<3#0H)#Z
M%"@"T4H/!UPRO?R5<_FF7,C,)J2Q[8.0U\QY2NB10<NHVZ[I0D4I-I!MG#XB
MZ2C0R39!,4BB8HU$-"5M,7\XSE..\QV;VK/M,62%[XO_`$5&8`(MP1I%14$W
M!&,(/PU"(I_&H4"!34&<JTQVA</W(_CDE%+%X_<],.6M*7"V4LBU+2RA%0,.
M*C:WF#./3D"7C)`R:A\A-7]04*!UA/M[`C7KH0I5;6]$N/VT?EWQY>^,F7!K
M-E\),<FX^>J-,42,JLO\J]+<4,";N/%1X=0%A8J`B!:4$.Y3ZZE;"Q>5,>(*
MO]VV)D>=N+E#[?BA@YZM.18#O>.MSZW025;&ZN`+NK^#0L%B7AUR$QKQ<\*.
M`,PY`QDED6ZK<Q0F\QS9*UB*7+<,G*C$,"-46#5Y%R4@@4O<W#VP*7;T$/2@
M%9?A7XV>7OF9Y#YNY.YFBYWC[%19G]YV/)/;'/;44K=PBJM9%L$C',8W;">'
M26^,L7941(->N@#$>,?G9R!XW9RF^!7D]XU.W-SM[A<1%AY^)B:*+;$^",@5
M*%C7LL-M.(P62T*E\HI^X4Q3I@.[J-0+<][WW:6-,>W=>\C(1D5:MFVA+W*D
MX=N6$5;@1\+#.)00;.T_B-4D@0;B&TIPH'I2F@/SP\G<V.2_D"XB>4C-]_W<
MM+8(L3)K:TL46ZRM1@U@C-DGT$S26B[F;Q973K<4VX3?+.8PB(UZZ`*M^SL2
M+_\`6SD*3XR3=$;Z2,42.#*K"*D'`&/O`RIQJ03#]/IH#1'[R=D5=3B"9558
MZ289!.1%1,`0WJ-H=-02B*8$5,8I`W>HTZ:`LW^%[MD\8G#4J3=%N!\21PG!
M!%-$JAP<.?S5`3*0#J&"@"8:B--`$N<D[-1*8A2J'2*0033W@9138;U((&`H
M#7TU=RJZXKC1^[$F5R3JFE0K%^3.?N*^^3N2VL<N"K3%N+H#'%O*%:MEC-;A
MO]_<:5P.OSD%4PD$XQ9GVQ*```@&X#!KZ0_;;*V<IHMK,0<G.\W.5=SV47+!
M'+ZGDK=^XU-R5.`,MY:ZSNZI"Y7:!#MK57<OVRRYW"2+N/@VC12%0<,&:J!7
MYR/EW0E1;D!903"!`KKV?*:A&ZU"ZZ17!.IR.;TG*Y=]?5/W?<0HOZ+;R6??
M[=AW;MBKB.'MNS$D2/G4?,/I@[F4<R3PZC)9H-N/#`FAUD"IE&@=!H.NGEH>
MA:]ENSGKU^,&L>E+XQ:-3>M6[>,*U,]SNRY69<F;;NM3*<OF5M9T>Y;1^/[D
M?1D7?5AD5%H<749%BE#IW<[1*SV$.S;.O:(UKN`=8N1\G^4_+&8_-:?>S#N?
MBC'_`(VXOWFLNWLU]*BU7>_YFOK:RDX^:$+D%)]CYQ%IO'PL;ICW5LM[>3<.
MVJ$L^;35Q)-X>7OK(KY9$6R)SN#1K;Y)"(HF.`AO,]H^B9^T]7E>OK,7%5I+
MP^I.+?O+F6SF:4E&<8+T?ZA/..&.<E9TR-#XTQ?"JPU\3<5%,KLFF"*SV(XJ
M87=1J:+2WXJ3<F>1ZV3+QB5&IW+QZI(**$,Y$I2G,!B^">>M8M:/8F[<HN*J
MEU5QVX+95^@[K1W*[12VT+=6#<,V5@/&]IXCL%!:'A+/A8V,^2(D4<W!(BDB
MYE+@=O'2:B[R3EWW=47'=L*98X$*0`+M^2=4U3-YW/.]>H^N7L6Y+'=LYG>V
M;,8P5*U2-Z;`^_\`Z_EJV5G`W00#_"-0_G]O_?0`N?*GXT[7\G^'+0PO=^0)
M:P(BWKM-=9W<*5B9](NFQ(]5HV(+^.DTRHI+QY3*43W"0PT$!H("N$W#8#UX
M^_MD.!.'K&N&&R1$RN8;IF6,Q'LKHG'3L5(0\S'DCP>,VL6A'I]]GM!1/<F8
MN[U`0Z:BA7WY<$0BQM^V<Y,<<<D7I>O%+GI*XJA;K>K?*CI&"CY-:8C#U!O&
MR[:0M9RP6;M$SF*G^44]##41U-!WY<$:KO']K%R4OS)2^9[EYP,9O+BDH1P>
M^_[=A&JB#ENH=:JD8TMIO&]Y516IR`W#\):`'U%INKJ6/_&YP\Y`<0[%NAER
M+Y-7#R7N^?<,CL))ZT9H,X",B4G"!(J*:QL/&((M/]X`@&TQZ%"IAIH0"US5
M^V]Q]R#Y[WMS.R+G*YC)2EZP5V,[%M$(]I\8(]^O(I-'JTA!R"AJJE(!NVJ4
M1*`T$-"J,G%U6T,#GOQA<(^3EZM+[SQA:!R-=$=!Q<,W?2WZH99NTBF[9JV`
M@M':`B/::E`=U1T*^]/D:KY$^/6./B6#MSA5CWC_`(LO2WC,&4=*W]CHTZ@2
M+CZ)HM!15,5)4I4DB@*BQ3JFI7>(U'0GO2Y`NN#7[<*U<0<K9?F)RSOR&ROD
M5>Z%;OMVRK68)0]A0ESNS'<&D&$.DR36;$:NUA%(A%@*&T!,`]1$6Y2<G5AW
M^0/!?B1RCFX"X>06"K'R1<-M,WC2#D;I),G/$-C-7+=(C`S"49L"[4E>N\IJ
M`(TH--"D[$;Q;QSAC#]Z8PXGVI;&!9:Y+;?I1%PVS"N'+-C*KME4$GJJA_GK
MKK(*%*<H&,:O3H.@*V6./VSE\9BY4W#RE\A7(-OF"X%YA"3C&MH-B1NY./,!
M6!%DU6"X;DD$$]P&&HFK3[`BA>[TN"+9$E8EG7%9I\>3\(TF[)<09+==VS,Q
MP+QDA#)LRL3M#MED06$Y&Z?0Q3`("?IJ2WURK7>1(Q_XU>".-K^@\FX_XQ8Z
MM"_+>5=JPTXT0FFTJQ[YVZJIF`#+_%,511`HF!1-2@@'H&A,IRDJ,$[Y<?`D
MIY.>2MJ9_#-I;%);N,W-G_VA\<@/W?<<1:@.0658N42(E!H(U-3:/J-1#0H/
M"QQ^W)BK5QG:-AS'-3D/)GM($T6C:"GK:3MNWD"HE3^';T?,V<_43:%V4VN#
M+'VE#K70&R&/@.09G=,6/.OE"SB53`?^WX&ZK3B&O=,.\)5ZFRLM$XODCCN*
M("5/<(U*/IH#IR/[?^,GP5/*<Y.3-PKI=IF28E9>R9"6(FW725,9216L!3MN
M44D>T"B>P0)T$:B.@"ZQ'#/&KKC,RXK9&>W3E;'S>#&#=S-X3AS34TR=`9)Z
M5T^MT(=0>Z@LH3W%`FT?30%<_E!X6>=4_8-]<+^,-QX&Q7P7GKI9W2,*E#22
M=].%078N!1=2[B:.FY(@=N%1,B8>GKH`P7B*\6%J^+CCVZQ3`W9*WG=-VF<3
MMZ7')+,CD6GG="@WATVS)CV8UJU11(7N@H?>41W"`AH`='E(\0G*_P`L.9<:
M1.4[]LC%>'L2KW`I!R$*W<.+DG&<T1H19,IQ=RS9%X@1J`F,=N4@[PH'0=`'
M\XD<?XOBEQQPWQY@I5]<D7BVT6MK-IR14:E>ODVAU%#.W!46[--0QS+#^!(M
M`#J&@-_."E33.;=W02(!D25`3F4*H8_H']-:5'T`-59&54HQ>UM>HMRP7L*_
M&<;&=S&2,R7@NQ(JA<&5Y2246!9!4PMK9M6U%HLHD(8R@$%Z98*4Z=1'UU]$
M>6\U'(:=;R\7X802W_#TFES+K)R>\B"UL!)PM)1`PYG396]H6V'CBI4%XYJX
M,JLI*LE%A*W4=-`6J3>51*OXBF]-=]H.8_4<Q*";\,:X57VG(ZXI.W'HVU`^
M61!ML@7SDJ_&S9S<8Y`N5U-R<_:R"]QW:$@V442^-=%B017MTN&J135[T:S;
MIA4?=T"G9J5[+QHG+VOX&HRN7G<>.\DW:T0\-;I'CU*)NS'\0N06C@%'[N,M
MDY1'I`9"LMVRD(93VC[;FDG9`$O4.@ZT^<6=S#I!RQ_$_O.AR^E0G2J_V_<3
M)@K+L'+T1%-[SA8"Y;<;H)?$@\E1S"9C7!"H[`<Q^1,?HPT2O(G4V*('=/EO
MC[?S.HZYG4/,V9T^+TZY*CMX5K-OW.AJLSIO;SDHI8)\N833AK8<%Q?M\B&)
M+3GFD=?,V,I?J<](,[J<74^$RY(Q!ID6/!:%(E&,EC$;M/E=T$B]2CL$0\7\
MTYJ.K7XWKDWW()]*3='7>U*NSCZCIM,M.U"BV.@:*#<GE&#%ZLT.GW2HJIM3
MG(92,_(ZHG6`=K@Q!]HF*)@$>NO+\U84;N/S+T;3KK3ET49DVK16,*&`I@K7
MWC0M`$:C3[@&F@`O>=?FYF#@;PI<9:P-*6_%Y8FK[M*Q[14N2.&1CSOKIG8J
M$#?N$K9OVOU$#"94Q2B&@("6MS?\@^!>?O!WC3EW(]G9TM_EMC:)O.Y$;8@F
M\/(68=Q\XTL<@'(@)AC6B1%"#M.50>@;O30!4>5GE-PWQCY$8ZXHD@KCR)R`
MR;;[JX[;LN.(5BS-$L5R(+N)">=-DX2-5*JIT*LNF8WJ`>N@/3\?'DOPUY"/
M^9(S&T+<%LW7@.\QMO*<'+,':3:,N%7YI$VQ)1RT38OQ.>-6WF;J'*4"`-0W
M!4`3U@^:#-S/FUS]@+GL"0R!QCXI))19WEF-6ZO]NRA7TD23%V_:D6.Y`B4<
M7:8!,4P5I70!KL9<Y<89@X@V_P`S<;1=U7-84[::%T1L!!6[*N9]ZH4S)HLP
M<-$HU5\51!:1*%#)E':!C>A3"`$,+J\SMA8AS+AO$F>,*9!Q:MGR62B\;SJK
M9>=;3SEPGW$`5_2&STL:(D.`F*OVQ+U#H(:`]SR4\[)3CIGGB!@BS\E*6=>7
M(B]T8F.MXMIR%QO)N.;+NROS?[*+?*129$6QQWKBF0:=/IH#;',?R>X?X9Y*
MPU@&XH.;R1GO-OQF=D65;YT6[V9[+,ZC^2>.E4A90+<OQE3;G)D`]O0>H:`Y
M\'O)[B'F]D+,V%;,AYFU<H8$EFT;?]N7`@K(HQJ@NV:;UFG+M$"QCU8"NMA3
MI*G)6GJ`#H"%4U^X&PK&9;Y!X3LCCSG;)]YX*G5(R898VMV5N@CHZ#=LJH85
M8V&E$6@G%7H6I:!3I7KH`Z.*;[<9,Q[;%\K6])VNM<,<SD1@Y-$6S]F#UNBX
M!!TDX3*=-9#O;%`$`$#E,%/IH#`^463'F$^/.:LKM'R2+['N-KQNQB^D>P1L
MT?1D6+EFF;VI)J$%5$?;U,/I]0T!4S\._GVY&Y_SCDFS^<KNT;6L5IC&XLCX
MTFCM&L`ZGT+97.F5"+#NI?/7>@[3`$BD.HH(!0!H.@-T>*KRW\Z>:ODJRE@;
M(D;9<+@6U(2>N>(ADX]%6ZO[42?%2C'[B6:NE.PJ9+;5NI14:C[>@Z`(/ECS
MK8"L:\,^PUG6==%^07%F97A\T7(V15@&\&_:NUF#M)LREVK5U/'161-T9E6$
M:5#0&^[^\OW$^P^$UC<[Y&1FBXWR>I&P=AP1(:0"Y[IN*X'"+>)B4(<L<,Q1
MPJ(_F]D$TP"IA#0`U[I\LG+&^?)SPFXLXWQPOB/'^4K+"^\F6Q=L<A+OW\`_
M@'4HS,$DU`Q(Y<X+HJ%`YBF``VF`3".@)MDYMRUV>6M+A59-\KMV-KV/)7=>
MMLE@)!PR29&C%5$E"7#\(\8FX5<.4P*CWMY!-^'IH#/\W^6'&]B\F9WB!BNP
M;OSAEZT+92N*_(.U63PS>VH4[4KI1RXE"MO@F<$95-VBJBH8W0"U'0$H[HY?
MQ-O\<+5STUQK?SM.Z@(R9V8O;\TA<D9)EE%806<Q'G8IOHY(SIN(E65333,D
M8JF[8("($1\;>7?'$[S"M[A+DO'=PXRS)>-LIW1:R1UR7!#/8NK@72BMQ197
M\&Q=-D$0.=LJN1?W``E]-`:'PWY">2F3?-IF/@\V;VH]X_X?QHE<<G.)QSM2
M1))22LR1HT*[:NBH`[4_2J`(D$A1#J%!"H!U;F<JL8"8?-D#*RJ,4\39MR5/
M5R9-86Q*!4M5%3`&FE)N[%?B5?:6;F$>8*:1L2YR1WQY1B<KV81,5^FJ4-WZ
MU,R+YN<PU$1WBR(@'\`#7KN5S,HV51X4YFFO[:&(N;!<0\0@]:`$;*"Q4F^^
MG%_J??F3"*$>@NV(V=#VESH&`QQ*&RGXBZK_`/7/R]U7[K48W(]-7UOV=+,.
MSE%G+SA2M%7=\395Y^++`&1+2MUQ$1S_``OEEK;;IHM?>,'A(M=24.5LJ960
M8+A(,%"=T]1+V`/01`=:>Q^[NH+/76YPO9>=RL8M373'A'%?U59FSTFU:A&B
MI)+EC[@:5Y<%LZX,D?UR][!>9#@&Q!,3,&#0;DG(1,>I#7%AQ565MN\""4*G
M^';:JE2CU#=U]7T+]Q<AF&K=^Y:C*F]37O;,&=QV,(K[3/\``-O(N9HJ,0:*
MN1P[4='?"Q;(8UOEHEOW$=W%8>5"LX,2*!42H1,.V6]0$.@4Q/,LH7\Q//8J
M%R22PP;?+:+=E9F2N[VOXVA(<%V4C,S[I-N0KMO%O#"K(IN'L,1-5-<"F9JV
M=(.&X@N`U'YK=F1N&T2@8`4`!\UUN-G*S[<VU<Z6U7@L-M.+6!L<O9Z'7[@E
M[5`&R"+=(`*5(A"!3_*``/K]M->=W)=<W-[S96VTZ([NK)DG`QR%$@&$`$PT
M+7[::`!KYQN"N?>=F)L%V?A!2'<_\;9K@LGW=`3BC8C.X8NV9&W)B/CZN'33
M</RX=01*4]1`U-`:CP/X[>4.1_(U:_/KE0K;%NP>),2I8VQ1C&TE$NTT`D6^
M9"Z6%M(2+A$#KO-PF[A!Z=!"F@-<<Q/&#R/NOR>V_P`[L7LK&RY:<=CP]K-L
M9W$YFXIW'N5'3A1T1.>)<,&BB98IB]2+E`.GUKH"?OC5X<3O%2S\S3\]8-F8
MLNK,EXK3)+&M234GF<2L=&0^%&W!.GF[A6E'B"[TVY8[PYJ&ZF]-`#'Q3XG^
M9%@\3O*O;;BX;48YPYJ9$F9"SE8Q&/<M&5N*O7QP!VN=RZ*54Z,A[*JDH`#4
M/30$S9;QS\AX'P_6=P5P+EEIB'-]O8^MQJ2^&!"+LW<E'LVWZ^S.4OR!!.35
MW$WD,6AC%,4P`&@!A8Z\,W+BZ^3W!W)F4X6V[8Q_QICU'604;ER#,9!GKSN#
M]-;HI7`S9)WS.JP@.7*2BH)@@B5/>!1*%*:`(SS+\=N?>3/E0X>\K8Y_!-L"
M\>8MV\6$YVYY\LB*"Y!^.@NZ,X$%5G!A&B`C0=`8!Y//&'FGDCSFXW\N,70E
MKY&B<00D@T>8PNN8>6RWFY9PW?K(S9[AB9^U9MF5LU<@B#=)^B!]E1((B(B!
M,;Q]\*Y'C6?-64G&,,9XFR=E].0DGT%9;NY9%$TL17NMPDI*[KGNB0?U6;$$
M5".A(-?70$=/#[XWLT\.LF\U\O\`(9U:\C<O)'*+^\X7]+:QTC)1\#M9(M"@
M4IY$P)B5H;V"6@C]!T`?=(A")MRE41202`H@FF0J(#0`$H"F`%*GUZB4`#K]
M-`0>\D.%,G<B>%_(+"6(UFZ-]91LB1M"&5?F3(R:A*LW;<SHQSJMRUW*!N`3
M]``.F@!6X3\"&%KAX^<1HODLW6;Y]X^VZ6+D)_'SK].C9]%!PBY6C)PS`7"#
MM!8R9-X&4]P5T![OCL\:.7>.W/SFWR=O@;6A,<9@CTX'!T/`_#4DV5JIN)X5
M5E$6SIVZHDD^:"(&(4=P!H"`F+O#[R>P+-<L+7F,4XDY&,>2V:[COJ(R=<MU
M3\":$M&XI*2>LD;V@U+_`($YUTDG)=I3MDQ,8!`"B/30$X.>?B2RIFWAYQ`P
M]Q]E+,MF\>)]_6#>C^RW$6LA8MQNX1,YY9JU&;7!15H1TH82[G1BT`*"(:`^
MX!\=_,BZO+07R#<GDK,@+>M_$D?8=EV[9<A&.8M)PS:Q3$Q2Q[27E5&B9VC5
M4P&H0M:``]0#0&=<.O'?R%QMY8^8'.G,DO`N\?Y-BFEJ8HAHOXRLBQ:-AA"]
MQP*#EPY*(IL%!.!BD"HC4*=-`:H1\??.3C1Y!N5O*7C<-A7G;?*>$AHE:2NL
MK)W+V>HT*R26!@#F3:KHD0,W,(E[8D.'00$!H($F/*#PZYI<L.,6,L<83S-`
MV?D&UGD#/Y"BFK=Q!1]^'8K,GDM#&GV:\<SA"JD;G3`0<MQZU`>H#H"#O#3Q
M/<EK,\D=D\Q,IQMK699EF8QAK.:X\2G'MZO33@*2))RXT[GDKBN8'`23=9':
MDFY'8*?4H`/4#TL4<)O(QQ>\BO,_F38V)L=9%B^14[%-+/925Y1#-Y!VU&GE
M!47*U4O-@N)4RRHG%,2>H?A^F@+1!NU[NYVJ5#=OV4K_`$[MW2OV5TA7_KV\
MOY$.F\QZ3&T]X!*!#=[>GL,L+/N=[=^2!0_%W]WX?ZJ^FLN/Y^GA[W3RZRB7
M9^KI]=#!G2.+3K%%5Y&I!^6(`1/<42[S;`]B)R]@3;J?TUK]^K%[NT_R>KI_
M'6G]0AVJ_P!OIKRI7W&UD09?&`$#$V;3`!@#\VM"[Q,`AW=_INJ%?2NL:/8K
MX>CJY4*W3ZAXFR@;-FVGMV;=NW[J=-NKWBYE"[-<.BOJ(N963XQKO%6][KV.
MQN10=K9_`E35O)!V)1]ZR-KIKSAQ(;\(*D$HA76QG^L="[GYKMX4KW*<J;B(
M]GZ.BG*AZ6!XJU(L7J</="%SNSMSF2<*QSB.D46/R$J)N4Y)@QDCG`PDJ)P'
MJ'76+>_-]7^1W>O\757WE2[>ZGN)*EK4/7U#5C$GPUW5'M05'$VSINVUK[=U
M/7[J_70'P]>E*UZ^G\M`-!ZCM]?K3UI4?6GWZ`^)[=OY6W94?]+;LK]:;/;7
M0'PGP]@[?C;>\.^G:V_*Z;MU.G?^VONT`\;_`"_:.[;]O3UI]=`-DV;R4V5V
MCLIMKV^E=E/Z*T].GIH!!\7OJ;?C_*[9>]3M]_M?T]RGYG;^RO30#I.WL#M[
M.W3V[*;*?6FWVTT`V?9N+397^G\-:[1KM^M=GV?T_=H!L>QW"]WL=S:.WN=O
MN;*#7;N]^S^'30#WY/=_]KO]L/\`!W>SN&G^?M[JT^E=`?1[/6O;^^NW_P`U
MT`YH!KV;![>W;N'=LI2O7=NV]*_;H#JD^+O;]OX^_M'^+L[6_L?E]SX^WKV?
MP[MOM]*_30'-7]/_`-UW_A_A1^;W>Q^'K\?Y6_\`I_P;_P"6@.V-*#6E*#6O
MI3ZUKTI30'`-O;+VJ;.FWMTV[:=-NWI30#)=E0V[*[C4V[?QT'?2G]=*U^OV
MZ`Y%]/9^&H_A]*U'=Z=*U]?OT`T/8V*[NSVJF^179VZT#=WZ^VNVE=WTT`ZE
KVMI-G;V=.UMV[*=?]+;[:?PT`X/9[A*]ON[3=NNWN;>F_97W;?2M-`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
